Your session is about to expire
← Back to Search
Other
SLC022 for Postherpetic Neuralgia
Phase 2
Waitlist Available
Research Sponsored by Solace Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 weeks
Awards & highlights
Study Summary
The purpose of this study is to evaluate the efficacy and safety of SLC022 in treating pain associated with post-herpetic neuralgia (PHN) in recently diagnosed patients.
Eligible Conditions
- Postherpetic Neuralgia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain
Secondary outcome measures
Determining the safety and tolerability of SLC022 300 mg TID compared to placebo TID in subjects with PHN by measuring changes in vital signs, ECG, hematology and other laboratory values, and subject-reported adverse events.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: SLC022Experimental Treatment2 Interventions
300mg TID
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo capsule
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
Solace PharmaceuticalsLead Sponsor
Kevin Pojasek, PhDStudy DirectorSolace Pharmaceuticals Inc.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger